Table 1 Ligands used in these studies
Ligand | Target | Mechanism of action |
|---|---|---|
Iloprost | IP = EP1 > EP3 > FP > EP4 > TP > EP2 | Agonist |
Treprostinil | IP > EP2 > EP3 > EP4 > EP1 > TP > FP | Agonist |
MRE-269 | IP | Agonist |
BMY-45778 | IP | Agonist |
Beraprost | IP | Agonist |
PGE2 | EP1–4 | Agonist |
Misoprostol | EP2 > EP3 > EP4 > EP1 | Agonist |
Butaprost | EP2, EP4 | Agonist |
AGN-205204 | EP4 | Agonist |
α-MSH | MC1, MC3, MC4, MC5 | Agonist |
Formoterol | β2 | Agonist |
Indacaterol | β2 | Agonist |
Salbutamol | β2 | Agonist |
Salmeterol | β2 | Agonist |
NECA | A3, A1, A2A, A2B | Agonist |
CGS-21680 | A2A | Agonist |
BAY60–6583 | A2B | Agonist |
Dopamine | D1 = D5 > D3 > D2 > D4 | Agonist |
Forskolin | AC 1–8 | Activator |
IBMX | PDE4, PDE3, PDE1, PDE5, PDE2 | Inhibitor |
Rolipram | PDE4 | Inhibitor |